|Bid||2.6200 x 47300|
|Ask||2.6300 x 3100|
|Day's Range||2.5900 - 2.7400|
|52 Week Range||2.1400 - 10.3200|
|Beta (5Y Monthly)||1.56|
|PE Ratio (TTM)||12.18|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Edible Arrangements is now selling fruit dipped in CBD-infused chocolate — dubbed "Incredible Edibles." Edible Arrangements Founder & CEO Tariq Farid joins Yahoo Finance's Zack Guzman and Kristin Myers, along with The Corporate Agent CEO and Founder Angelique Rewers, to discuss.
CBC report says Ontario will open more stores, making it easier for licensed producers to get their product to consumers.
SAN FRANCISCO, CA / ACCESSWIRE / December 14, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Aurora Cannabis Inc. ("Aurora" or the "Company") (ACB). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. The investigation concerns whether Aurora and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
NEW YORK, NY / ACCESSWIRE / December 13, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. A class action has commenced on behalf of certain shareholders in Infosys Limited.
SAN FRANCISCO, CA / ACCESSWIRE / December 13, 2019 / Hagens Berman urges Aurora Cannabis Inc. (NYSE:ACB) investors who have suffered losses in excess of $200,000 to submit their losses now to learn if ...
NEW YORK, NY / ACCESSWIRE / December 13, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered ...
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aurora Cannabis Inc.
It has been a rough ride for shares of Canadian cannabis producer Aurora Cannabis (NYSE:ACB) in 2019. Aurora began the year priced around $5. However, it's exiting the year at around half of that value -- mostly thanks to stagnant revenue growth amid challenging demand trends in its core Canadian consumer market.Source: Shutterstock But, I think that 2020 is shaping up to be a great year for Aurora Cannabis.The contrarian bull thesis here is simple. Those challenging demand trends in the Canadian consumer market will turn around in 2020. This is due to the launch of new products like edibles and vapes, a reduction in legal channel supply constraints and an expanded retail distribution footprint.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAs those demand trends turn around, Aurora's revenue growth will re-accelerate higher. This resurgence, coupled with favorable U.S. legislation progress, will spark a big rebound for Aurora. * These 7 S&P 500 Stocks Will Deliver a Repeat Performance in the Next Decade As such, although it's easy to write off Aurora Cannabis as a falling knife at this point. I ultimately think that dip buyers who exercise patience at these levels will be rewarded in a big way over the next 12 months. The Canadian Cannabis Market Will Bounce BackThe Canadian cannabis market looks poised for a big rebound in 2020 after a rough 2019.The big problem with the Canadian cannabis market in 2019 was that consumer demand in the legal channel fell flat. That happened for a number of reasons, all of which come back to this idea that the legal channel failed to pull that much demand from the black market.That said, the black market had lower prices because they didn't have to pay legal or regulatory fees. They also didn't have any supply issues -- whereas nascent legal suppliers had huge supply constraints. They were also able to get product to consumers in a timely manner -- whereas legal suppliers were still learning the ropes of cannabis distribution and logistics -- and offered a wider array of products that legal suppliers couldn't sell.Fortunately for those interested in investing in the Canadian cannabis market, all of that will change in 2020.First, that Canadian government is aware that the black market is outpricing the legal market, and there appears to be legal steps being made to rectify this issue. Second, legal suppliers have spent all of 2019 increasing growing capacity. So, come 2020, there should be no more supply constraints. Third, legal suppliers are also aggressively expanding their retail footprint throughout Canada, and that should lead to improved logistics. Fourth, the legal market will able to sell cannabis 2.0 products like vapes and edibles in 2020.Therefore, 2019 cannabis market demand headwinds should turn into 2020 demand tailwinds. As they do, everything will improve for cannabis companies. Revenue growth rates will ramp back up, margins will improve and net losses will shrink.As all those things happen, pot stocks should bounce back. It also doesn't hurt that the U.S. is inching towards federal legalization of cannabis with the House Judiciary Committee recently passing the Marijuana Opportunity, Reinvestment, and Expungement (MORE) Act. Aurora Will Bounce Back, TooAs the cannabis sector bounces back in 2020, Aurora will bounce back, too.I like Aurora Cannabis in the cannabis sector for a few, very simple reasons. First, the company is very big in this world. They are second to only Canopy Growth (NYSE:CGC) in terms of sales and growing capacity. After those two, it's a steep drop off to the rest of the pack.Second, they have a strong leadership position in the markets in which they operate. In the Canadian consumer market, Aurora owns the top three best-selling cannabis consumer products in Ontario -- Pink Kush, Blue Dream and Tangerine Dream. Internationally, the company has a leadership position in medical marijuana throughout most of Europe.Third, Aurora is supported by favorable margin trends. Gross margins here are high for the cannabis industry, up near 60% last quarter. Those gross margins are also stable, and haven't changed in several months. At the same time, management is exercising disciplined cost control, while selling, general and administrative expenses dropped 1% quarter-over-quarter last quarter.Fourth, the valuation on Aurora is favorable relative to other pot stocks. Aurora's market cap presently stands at $2.7 billion. Revenue estimates for two years ahead stand around $950 million. That gives Aurora Cannabis a two-year-forward sales multiple of less than 3. Peers Canopy Growth, Tilray (NASDAQ:TLRY), and Cronos (NASDAQ:CRON) all trade north of four-times sales that are two years out.All in all, there are a lot of positives which make Aurora stand out in the cannabis sector in a good way. Those positives ultimately mean that if the cannabis sector rebounds in 2020, Aurora could rebound by even more. Bottom Line on Aurora CannabisYes, Aurora looks like a falling knife. In 2019, it was. But, in 2020, it won't be.Instead, Aurora's awful 2019 performance actually sets the stock up nicely for a big 2020 rebound amid a significant reversal in Canadian consumer market demand trends.As such, I think patience will be rewarded here. There's no need to rush and buy the dip just yet. Instead, be patient. Wait for signs that the turnaround is emerging. Then, buy the dip and hold for the big 2020 rally.As of this writing, Luke Lango was long CGC. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 10 Worst Dividend Stocks of the Decade * 7 Game-Changing Tech Stocks to Buy Now * 5 Chinese Stocks to Buy for the Big 2020 Rebound The post Patience With Aurora Cannabis Will Pay Off in 2020 appeared first on InvestorPlace.
The Canadian cannabis stocks continue to trade near the yearly lows and the Cannabis 2.0 rollout can’t start soon enough. Unfortunately, Canopy Growth just confirmed the process isn’t going to be smooth or as quickly as the market expected.Earlier this year, Canada regulators established the rules for the rollout of edibles, vapes, beverages and other cannabis products falling into the Cannabis 2.O category. Investors have big hopes for these products to provide cannabis stocks with a boost in revenues from product categories that won’t face the same competition from illegal sources.The government organization allowed companies to submit products for license beginning October 15 with a 60-day review period providing an initial sales date of December 16. As Canopy Growth acknowledged last week, the products can’t be sold into the distribution channels until that day pushing the date before reaching store shelves until sometime in early January 2020.As with the Cannabis 1.0 rollout last October, the Canadian market continues to face failure after failure in reaching aggressive sales targets. The market had originally expected Cannabis 2.0 products to be available starting mid-October and now most store shelves will remain empty until way into Q1.In addition, these products will still lack vast distribution in areas like Ontario already holding back Cannabis 1.0 sales. In addition, provinces like Quebec are limiting 2.0 products while Newfoundland and Labrador aren’t allowing vapes. Investors need to consider that two key provinces are effectively limited at the initial Cannabis 2.0 rollout with Quebec limiting sales and Ontario still lacking stores.We’ve delved into these four Canadian cannabis companies set to lead the market in the Cannabis 2.0 wave after the expected dominance of Canopy Growth:Aurora Cannabis (ACB)Aurora Cannabis is the other major player in the industry expected to have a wide selection of Cannabis 2.0 products ready when the market opens up in mid-December. The company plans to have a wider selection of edibles with chocolates, mints, cookies and gummies hitting the market in addition to a selection of vapes and concentrates.The company arguably has the second-best Cannabis 2.0 lineup and interestingly avoided the beverages market out of the gate. Aurora Cannabis hasn’t had the same problems with recreational cannabis with returns like other leading companies so one might wonder if their placement in the edibles market over beverages isn’t a market signal.With a market cap heading towards $3.0 billion, the stock is probably less reliant on a home run from Cannabis 2.0. Investors have bigger concerns about cash balances and any positive results from selling edibles definitely helps at the margins. The big benefit to Aurora Cannabis is to place the costly ramp up period in the rearview mirror, allowing the company to shift towards streamlining operations in order to generate profits.TipRanks suggests caution has Wall Street fairly divided in its expectations on ACB. The stock currently has a Moderate Buy consensus rating, which breaks down into 5 "buy" ratings vs 4 "hold" and 2 "sell" ratings. (See Aurora's price targets and analyst ratings on TipRanks)Organigram (OGI)Organigram is coming off a rough quarter so any good news would be highly welcomed in this stock. The company isn’t the most aggressive heading into the Cannabis 2.0 launch, but a position in vapes and chocolates could be the best conservative play in an unclear market demand picture while conserving precious cash.The company recently ran into problems with products returned from the Ontario Cannabis Store. Both THC oils and low THC dried flower failed to sell as expected and the lack of retail stores in Ontario didn’t help so a more conservative rollout of 2.0 products might be the smart move.Organigram is taking a more cautionary move into these products with a focus on what was successful in U.S. due to a lack of actual knowledge on the desired products in Canada. The Canadian LP will have vape pens and edibles ready for sales to mirror the products most successful in the U.S.Vape pens available in December will use the PAX Era platform and Edison pens from Organigram. In addition, the company has exclusive license to the Feather products popular in Colorado providing multiple solutions to attack the market.As the market develops in Q1, Organigram will roll out chocolate products from their new $15 million production line. The company plans to pursue co-manufacturing and private labeling to fully utilize this new facility.The company has additional plans for a powered beverage in Q2 to round out a complete Cannabis 2.0 lineup without rushing products out the door in December before the market matures and Ontario opens more stores. With a market value of only $400 million, the stock could see the biggest boost from a successful rollout of products like vapes and edibles.All in all, Wall Street loves this stock, earning a stellar analyst consensus rating, as TipRanks analytics demonstrate OGI as a Strong Buy. Out of 8 analysts tracked in the last 3 months, all 6 are bullish on Organigram stock, while 2 remain sidelined. With a return potential of over 130%, the stock's consensus target price stands at $6.21. (See Organigram stock analysis on TipRanks)Tilray (TLRY)Tilray is the wildcard in the Canadian cannabis sector. The company is relying on wholesale supplies to fuel a Cannabis 2.0 lineup that initially includes CBD beverages, edibles and vape products.Tilray will utilize their High Park Holdings business to lead the rollout of new products including beverages. The company will bring existing U.S. brands of Marley Natural and Goodship to Canada along with other new brands like The Batch, Chowie Wowie and Rmdy. The portfolio will include vapes, cannabis-infused baked goods, gummies and oils.The most focus is naturally on the joint venture with AB InBev (BUD) named Fluent Beverage Company. A major distribution partner in the beverage space is a big feather in the cap of Tilray, yet the company is still lacking a THC product from the start. In addition, the JV is only 49% owned by Tilray so the sales won’t be consolidated on the income statement. Investors expecting a big sales boost might be disappointed with the quarterly results.The company has a market cap of $1.8 billion and quarterly revenues are still making a slow ramp. Analysts only target March quarterly revenues of $65 million, a $10 million boost from the prior quarter. Over time, the hidden value in the stock could come from the Fluent Beverage JV.According to TipRanks, the consensus on Wall Street is that Tilray stock is a “hold” for investors. But TipRanks might as well have said “buy” — because analysts, on average, think the stock, currently at $18.99, could zoom ahead to $26.50 within a year, delivering 39% profits to new investors. (See Tilray's stock-price forecast and analyst ratings)Canopy Growth (CGC)Canopy Growth is the expected leader in the Cannabis 2.0 phase along with all of the U.S. listed Canadian cannabis stocks. Most of the partnerships and direct investments from global firms were for the new product forms such as beverages.The company has held several media and analyst events to prime the investor community on the products hitting the cannabis market on December 16. Canopy Growth has a broad depth of products in the beverages, vapes and chocolates categories, but the company does appear lacking in amount of different product categories with no gummies or other edibles.Considering the Constellation Brands (STZ) investment and the large beverage capacity from the new Smith Falls facility, one shouldn’t be surprised the company has a wide selection here. Canopy Growth plans to offer ten ready-to-drink products and three purely distilled cannabis drinks with multiple flavors and mg levels of both THC and CBD.The problem for the stock is that their beverages and vapes won’t reach stores until early January. The benefit to the current December quarter won’t occur and the new CEO from Constellation Brands doesn’t start until January 14. The company faces a ton of disruption in the next month or so that will impact short-term results.Canopy Growth has a market value of $6.5 billion and a lot of value is based on the Constellation Brands deal and the related breath of beverage offerings. A failed uptake of THC and CBD infused beverages would seriously damage the value of a stock with a business generating quarterly EBITDA losses of C$100 million and needing a new winning strategy to turnaround the prospects of the company.To find good ideas for cannabis stocks trading at fair value or better, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to firstname.lastname@example.org.
NEW YORK, NY / ACCESSWIRE / December 13, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.
Cannabis stocks rallied out of the gate Friday, after a report that the Canadian province of Ontario will open up the market for retailers with plans to issue abut 20 new store approvals starting in April of 2020. The news reported by Canadian network CBC eased concerns about the shortage of stores that has hampered the development of the legal cannabis market in Canada and allowed the black market to continue to thrive. "This is certainly better than the status quo," said MKM analyst Bill Kirk. "In the fight to take share from the illicit market (which has ~80% share), access to stores has been a major issue." he cautioned, however, that access is not the only obstacle the market is facing, highlighting quality and price as other major issues. A survey conducted by MKM found Canadian consumers using the black market due to price convenience and also quality. "Further, Canopy teased an expectation for 40 Ontario stores per month beginning in January," said Kirk. "If the details of 20 store/month beginning in April hold true, Ontario would have 62% fewer stores by year-end 2020 than Canopy had expected (480 vs 180). All else being equal, we would recommend selling into any strength this news may produce." Canopy shares rose 5%, Aurora Cannabis was up 5.2%, Cronos was up 3% and Tilray rose 2.5%. MedMen rose 11%, Aleafia rose 5% and Organigram added 5%.
The past six months haven't been great for Aphria (NYSE:APHA), but shares haven't fallen as far as the company's more famous peers. Aphria stock is down 27.7% in the past six months. In contrast, the more popular "pot stocks" are down much more. Shares in Aurora Cannabis (NYSE:ACB) dropped 66.5% in the same period. Hexo (NYSE:HEXO) has fallen 61%. Canopy Growth (NYSE:CGC) is down 50.9%.Source: Shutterstock Why hasn't APHA stock performed as badly? Perhaps it's because Aphria has historically traded at a discount to its competitors. Back in September, Aurora, Canopy, and Hexo were trading at enterprise value/sales (EV/Sales) ratios north of 30. At the same time, Aphria's EV/Sales was just 9.5.Today, Aphria trades at an EV/Sales ratio of 6.7. While it is by no means a "value stock," APHA remains a relative bargain.InvestorPlace - Stock Market News, Stock Advice & Trading TipsDoes this mean its time to buy? Let's take a closer look. Growth is priced into shares, but this overlooked pot stock could be a diamond in the rough. Aphria Marches Towards ProfitabilityAPHA may be an also-ranb pot stock, but the company is no slouch when it comes to market share. Aphria has supply agreements across all of Canada's provinces. This gives them access to 99.8% of the country's population. * The 10 Worst Dividend Stocks of the Decade Oversupply in Canada is an issue, yet Cannabis 2.0 could spur demand. But unlike Canopy or Hexo, Aphria has not announced a big infused beverage launch. Yet, Aphria does have Cannabis 2.0 exposure. Back in June, the company announced a partnership with Pax Labs to develop cannabis vape products.Over in Europe, Aphria is betting big on medical marijuana. Especially in Germany. The company is one of just three to obtain a cultivation license there. The company's German unit CC Pharma is the biggest piece of the Aphria pie, making up 74% of net revenues. Aphria is also a big player in Latin America, via its acquistion of LATAM Holdings.The company's peers are hemorrhaging cash. But Aphria stock posts quarterly positive EBITDA. The company's strategy appears to be paying off. But why does Aphria continue to trade at a low valuation? Why is APHA Stock So Cheap?Aphria trades at a sharp discount to peers. As I mentioned above, Aphria's current EV/Sales ratio is 6.7. In contrast, Aurora Cannabis has an EV/Sales ratio of 14. Hexo also trades at an EV/Sales ratio of 13. Canopy's EV/Sales ratio is 21.9.But there is a reason behind the discount. Aphria has a bad reputation among investors. Prominent short-seller Hindenburg Research lambasted the company in December 2018. This was due to accusations some Aphria insiders engaged in self-dealing. Aphria has been able to salvage its reputation after a management shakeup, but Wall Street still gives Aphria a skeptical eye.Aphria's strong balance sheet ought to counter this. The company has $348.8 million in cash and short-term investments. Aphria does have an equally-sized debt load ($356 million). But as InvestorPlace's Ian Bezek recently pointed out, Aphria has no problems obtaining credit.Competitors have had more trouble raising capital. Yet Aphria was able to obtain attractive financing for its Diamond production facility. Aphria lacks a strategic partner like Constellation Brands (NYSE:STZ) or Altria Group (NYSE:MO). But the company has avoided the capital crunch seen with Aurora. The Bottom Line on Aphria StockAphria stock has a clear path to profitability. Yet, shares trade at a discount to peers. Past scandals continue to tarnish the stock. But for investors playing at home, run the numbers. The company has more going for it than Wall Street gives credit.But does this make APHA stock a buy today? Perhaps. Analyst consensus projects positive earnings-per-share in 2020 and 2021. Meanwhile, names like Aurora and Canopy will remain unprofitable. The bigger names dominate the headlines. But under-the-radar Aphria may be the best "pot stock" buy.I remain on the fence with regards to pot stocks. I'm waiting for valuations to fall to more reasonable levels. But if you have pot stock FOMO and worry today's prices will be a bargain in hindsight, consider APHA.As of this writing, Thomas Niel did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 10 Worst Dividend Stocks of the Decade * 7 Game-Changing Tech Stocks to Buy Now * 5 Chinese Stocks to Buy for the Big 2020 Rebound The post Consider Aphria Stock as the Cannabisphere Burns appeared first on InvestorPlace.
Near the end of November 2019 Aurora Cannabis (ACB) found it would no longer be able to sell medical cannabis to the German market until the company obtains a permit to sell cannabis that has undergone ionizing irradiation.In this article we'll look at the impact the temporary loss of sales in Germany will have on the company.IrradiationMany investors have thought that having facilities approved of for the stringent guidelines associated with European Union Good Manufacturing Practice (GMP) were enough to sell into Germany.But the recent discovery that Aurora Cannabis wouldn't be allowed to sell medical cannabis in Germany until it achieves a specified level of microbiological quality related to the flower.That must either be accomplished by extremely clean facilities that meet the German requirements, or have the flower irradiated, which is a process that decontaminates the flower.If a company must irradiate to conform to required microbial levels, it also has to apply for a permit that allows irradiated cannabis to be sold in the German market.Any importer into the German market will have to apply to the Federal Institute for Drugs and Medical Devices (BfArM) for every flower variety that will be distributed in Germany.As of this writing, the cost per application was just under US$4,951.Aurora management believes it will take about a month or so to get approval to sell irradiated cannabis in Germany.According to CCO Cam Battley, the company "realized" it needed a permit, suggesting it simply forgot about it or didn't perform due diligence concerning the requirements.ImplicationsCombined with other challenges related to revenue growth in the short term, including the lack of cannabis retail outlets in Ontario and the time it will take to ramp up derivative sales, the loss of sales in the German market is going to make a challenging fourth calendar quarter even more challenging for the company.How much it will impact its performance will depend upon how much demand for derivatives will drive the last couple of weeks of December sales. If it has more than adequate supply to meet pent-up demand, it could to some degree, offset the decline in German sales in December.Battley expects sales in Germany to resume in early 2020.With expectations already low for the current quarter, I don't think this is going to be a big deal for Aurora unless its sales decline even further because of the slow pace of retail stores opening, and derivatives have no immediate impact on revenue in December.The bigger issue is how this will impact long-term German sales because of Pharmacies possibly being reluctant to use Aurora because of being perceived as an unreliable and consistent source.In the past I've mentioned this was one of the strengths of Aurora, and if it falters there, it international potential would be diminished for a couple of quarters, until it wins back the trust of the Pharmacists.That may not happen. But because Aurora is not allowed to sell in Germany, medical cannabis patients will have to get their product from another source. Whether or not they return to Aurora is a significant issue over the long term.Analyst CommentaryThe market has divided itself into two camps. The bulls argue that the worst is behind Aurora, while the bears argue that the market is too optimistic about Aurora's recovery, which could take a long, long time. Piper Jaffray analyst Michael Lavery has found himself in the middle. The analyst rates the stock a Neutral alongside a $3.00 price target, which implies about 15% upside from current levels. (To watch Lavery's track record, click here)In a research note issued yesterday, Lavery wrote, "It may take time to recover lost German sales. The temporary sales halt could have a lasting impact in the German medical cannabis market. According to our contact in the EU, doctors tend to prescribe products that have strong track records of availability. Aurora's current patients will have to be prescribed a competitor's product while Aurora pauses sales, and it could be challenging to switch them back again. Additionally, it could take longer than expected for Aurora to begin selling products in Germany again as it typically takes months for German regulatory approval of products, and German regulators are used to reviewing applications for gamma radiation (not e-beam sterilization). Aurora is confident that sales can continue early in the new year, but there is some uncertainty in the process timeline."If we turn to the Street in general, we can see that sell-side analysts are fairly divided in their expectations on Aurora stock. Out of 11 analysts tracked by TipRanks in the last 3 months, 5 say "buy," 4 suggest "hold," and two recommend "sell." (See Aurora stock analysis on TipRanks)ConclusionWe won't know until the next earnings report the level of revenue Aurora has lost because of having to wait to receive its permit. Worse, it won't be until the following earnings report that we discover whether or not former customers have come back to the company after having to use alternative sources.One positive here is it appears there is demand from German patients for some derivative products. If so, that could be an attractive and compelling reason to once again choose Aurora as the preferred distribution source.To me, the major issue here is it once again places uncertainty over the company at a time when it needed to provide a clearer picture of its future short- and long-term outlook.Now what we have is the ongoing concerns over the pace of retail cannabis stores opening in Ontario, how much impact derivative products will have on Aurora's revenue, and how long it will take it to recover and grow sales in the important German medical market.In my view, the next couple of quarters are going to be vital to the company. At this time I think the negative surrounding the lack of retail stores is already priced in, but if there is any disappointment in derivative or German sales over the next two quarters, Aurora is going to have a difficult time maintaining support levels.Over the long term I remain optimistic over its prospects, but it could go through a prolonged period of growing pains if it doesn't do well in the first half of calendar 2020.To find good ideas for cannabis stocks trading at fair value or better, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
In late November, Aurora Cannabis Inc (NYSE: ACB ) (TSE: ACB) CEO Terry Booth told BNN Bloomberg that his company has its sights set on the United States market. "Carnage" could be ahead for ...
NEW YORK, NY / ACCESSWIRE / December 12, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
Germany recently halted Aurora Cannabis (NYSE: ACB) product sales, until the health authorities investigate the production process. The production step awaiting for the inspection is related to a method that Aurora utilizes to attain a long shelf life of the flower, German pharmacies reportedly said. Battley was alluding to the special permit that's demanded for distribution of irradiated medical cannabis products in Germany, adding “it’s going to take about four weeks” for the company to acquire it, according to Marijuana Business Daily.
Pomerantz LLP is investigating claims on behalf of investors of Aurora Cannabis Inc. (“Aurora” or the “Company”) (ACB). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. The investigation concerns whether Aurora and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
NEW YORK, NY / ACCESSWIRE / December 11, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Investors Affected : shareholders who acquired: (a) Domo common stock pursuant and/or traceable to the Company's initial public offering commenced on or around June 29, 2018; or (b) Domo securities between June 28, 2018 and September 5, 2019, both dates inclusive.
NEW YORK, NY / ACCESSWIRE / December 11, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...